NEWS
BioTuesdays I Bolt pioneering new approach to cancer immunotherapy

Bolt Biotherapeutics (NASDAQ:BOLT) is developing tumor-targeting therapies that leverage the power of basic components of the innate and adaptive immune systems to attack the tumor microenvironment. “We’ve demonstrated preclinically that this approach allows us to train the immune system to recognize and destroy a tumor, as well as leave a subject with an immunologic memory of […]

Cell and Gene I DTx Pharma And The Near-Term Future Of RNA Therapeutics

DTx Pharma is a therapeutics company focused on solving one of the biggest challenges limiting the expansion of genetic medicines as a therapeutic class: the delivery of RNA therapeutics beyond the liver. To learn more about the near-term future of RNA therapeutics, the advantages of short interfering RNA (siRNA) over other RNA therapeutics and more, […]

Oncology Tube I CODAGENIX: WHAT IS CODALYTIC? WHO’S THE TARGET?

Could Oncolytic Viruses Be Dangerous? CodaLytic is a novel Oncolytic virus that Codagenix, Inc is developing in the context of breast cancer. Oncolytic viruses in general are a relatively novel modality. These are live viruses (or live vaccines) engineered in a way that they can specifically infect and replicate, and cancer cells destroy some of […]